Cellebrite DI Ltd.
CLBT · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $4 | $5 | $5 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | – | $4 | $5 | $5 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 11.3% | 5.3% | -1.4% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 83.9% | 84.4% | 83.7% | 83.8% |
| EBITDA | $0 | $0 | $0 | $0 |
| % Margin | 21.4% | 15% | 13.9% | 16.9% |
| Net Income | $0 | $0 | $0 | $0 |
| % Margin | 16% | 17.2% | 16.2% | 17.7% |
| EPS Diluted | 0.08 | 0.078 | 0.07 | 0.078 |
| % Growth | 2.3% | 11.7% | -10.1% | – |
| Operating Cash Flow | $0 | $0 | $0 | $0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | $0 | $0 | $0 | $0 |